Vaccine Efficacy after Rituximab Exposure: First Interim Analysis of Virtue Project on Behalf of West Midlands Research Consortium, UK

Background: Anti-CD20 B cell depleting agents are amongst the most commonly used immunotherapeutics employed in the treatment of haematological malignancy and autoimmune diseases. By inducing peripheral B cell aplasia, anti-CD20 depleting agents are hypothesised to significantly impair serological r...

Descripción completa

Detalles Bibliográficos
Autores principales: Shields, Adrian M, Venkatachalam, Srinivasan, Paneesha, Shankara, Ford, Mark, Sheeran, Tom, Kelly, Melanie, Karim, Farheen, Qureshi, Iman, Salhan, Beena, DeSilva, Neelakshi, Stones, Jacqueline, Lee, Sophie, Khawaja, Jahanzeb, Kaudlay, Praveen Kumar, Whitmill, Richard, Nabikakepoto, Ghulam, Faustini, Sian E, Richter, Alex G, Drayson, Mark T, Basu, Supratik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
203.Lymphocytes and Acquired or Congenital Immunodeficiency Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701526/
http://dx.doi.org/10.1182/blood-2021-150220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701526/
http://dx.doi.org/10.1182/blood-2021-150220

Ejemplares similares